/
Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. We help our customers deliver the best possible patient care through industry-leading products, solutions, and technology.
Operating margin is thin at 7.95%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 8.3%, steady but not accelerating. Free cash flow declined 24% despite revenue growth, conversion is weakening.
Free cash flow declined 24% versus the prior year, cash generation momentum has weakened.
Profitability & Returns
Revenue (TTM)
$2.81B
▲ +8.3% YoY
Net Income (TTM)
$68M
▲ +104.2% YoY
Op. Margin
8.53%
▲ +49.3pp YoY
ROIC
4.03%
▲ +19.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$220M
▼ -23.9% YoY
Op. Cash Flow (TTM)
$272M
▼ -18.1% YoY
Net Debt
$506M
Cash & Equiv.
$1.08B
5Y CAGR: +7.1%
5Y CAGR: -0.5%
Continue Research